Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline candidates for prescription if approved. Exton, PA., July 24, 2024 – The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking advancements in gene therapy for retinal disorders. […]
Evaluating the Efficacy and Perception of HS Treatment Options
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing hidradenitis suppurativa (HS) effectively remains challenging for dermatology clinicians, necessitating innovative and effective treatment options. Recently, Spherix Global Insights took a deep dive into secukinumab (Cosentyx; Novartis) versus adalimumab (Humira; AbbVie) in HS treatment performance.1 […]
Conflicting Views Between Epileptologists and General Neurologists Hinder Adoption of New Refractory Epilepsy Treatments
New brands aiming to enter the refractory epilepsy market may face challenges achieving desired penetration without improved general neurologist education efforts, according to Spherix Global Insights. EXTON, PA., July 8, 2024 – Chronic epilepsy is often well managed by neurologists, but a sizable proportion of adults with epilepsy continue to experience seizures at varying frequencies […]
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
Ophthalmologists are cautious about prescribing the current geographic atrophy (GA) treatment options Syfovre and Izervay, introduced in 2023 as the first-ever therapy for GA, according to Spherix Global Insights. EXTON, PA., June 27, 2024 – Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in […]
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Continued Unmet Needs and Track New Launches
Spherix Global Insights releases market landscape evolution study paired with new research tracking familiarity and uptake of Novartis’ Fabhalta and Alexion/AstraZeneca’s Voydeya. EXTON, PA., June 26, 2024 – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells prematurely break apart, a process known as hemolysis. While the symptoms can vary […]
Novartis’ Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
Pending regulatory submission, Fabhalta (iptacopan) could become the first approved therapy for C3G, addressing a significant unmet need in nephrology, according to Spherix Global Insights. EXTON, PA., June 13, 2024 – Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are no therapies specifically […]
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to Spherix Global Insights. EXTON, PA., May 9, 2024 – Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape has remained relatively stagnant. Yet, neurologists […]
